Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To
Loading page…
Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease (2018 archive) | oneSCDvoice